As Imbruvica bows out, AstraZeneca clinches early Calquence win in newly diagnosed MCL

As AbbVie and Johnson & Johnson’s Imbruvica retreated, AstraZeneca’s Calquence has become the first BTK inhibitor to claim a unique win in previously untreated mantle cell lymphoma (MCL).